Horizon Pharma PLC (HZNP) Given Daily News Sentiment Rating of 0.20
Press coverage about Horizon Pharma PLC (NASDAQ:HZNP) has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Pharma PLC earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.1200648815445 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Horizon Pharma plc to Host Third-Quarter 2017 Conference Call and Webcast on Nov. 6, 2017 – GlobeNewswire (press release) (globenewswire.com)
- Horizon Pharma plc to Host Third-Quarter 2017 Conference Call and Webcast on Nov. 6, 2017 (finance.yahoo.com)
- Zacks: Brokerages Anticipate Horizon Pharma PLC (HZNP) Will Post Quarterly Sales of $254.14 Million (americanbankingnews.com)
- Horizon Pharma Breaks Above 200-Day Moving Average – Bullish for HZNP (nasdaq.com)
- Jefferies Group LLC Reaffirms Buy Rating for Horizon Pharma PLC (HZNP) (americanbankingnews.com)
A number of analysts have recently weighed in on HZNP shares. BidaskClub raised Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. UBS AG set a $16.00 price objective on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 price objective on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Monday, August 7th. Cantor Fitzgerald set a $13.00 price objective on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Monday, July 31st. Finally, BMO Capital Markets reissued a “buy” rating and issued a $17.00 price objective on shares of Horizon Pharma PLC in a research report on Friday, July 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $18.00.
Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 13.70 on Wednesday. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The firm’s 50-day moving average price is $13.02 and its 200-day moving average price is $12.71. The firm’s market cap is $2.24 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. During the same quarter in the prior year, the firm posted $0.56 earnings per share. Horizon Pharma PLC’s revenue for the quarter was up 12.5% on a year-over-year basis. Analysts expect that Horizon Pharma PLC will post $1.07 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/horizon-pharma-plc-hznp-given-daily-news-sentiment-rating-of-0-20/1623269.html.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.